India Pharma Outlook Team | Friday, 05 June 2026
India’s drug regulator, the Central Drugs Standard Control Organization (CDSCO), has directed pharmaceutical companies to strengthen pharmacovigilance systems, mandating immediate compliance to monitor and report adverse drug reactions (ADRs).
The move reflects a sharper regulatory focus on post-market drug safety as India continues to play a pivotal role in supplying generic medicines globally.
Under the directive issued on June 3, all pharmaceutical manufacturers, marketers, and importers are required to establish and maintain robust pharmacovigilance frameworks in alignment with existing regulatory provisions, including the New Drugs and Clinical Trials (NCT) Rules, 2019.
The regulator has also made it clear that compliance will be closely scrutinized during routine inspections by CDSCO officials, state licensing authorities, and Union Territory regulators.
The directive comes at a time when global scrutiny on the quality and safety standards of Indian pharmaceutical products has intensified. India supplies nearly one-fifth of the world’s generic medicines by volume, making the integrity of its drug safety systems a matter of international importance.
Pharmacovigilance, the science of detecting, assessing, and preventing adverse effects of drugs, has increasingly become a critical component of regulatory compliance worldwide. CDSCO’s move signals a shift toward strengthening post-market surveillance, ensuring that drug safety monitoring continues even after products are approved and widely used.
As part of the mandate, pharmaceutical licenses must designate qualified pharmacovigilance officers responsible for overseeing safety monitoring activities. Companies are also required to maintain comprehensive records of all reported adverse drug reactions and implement standard operating procedures (SOPs) for systematic data collection and reporting.
The directive draws from provisions under the Drugs & Cosmetics Act, 1940, particularly Schedule M, which mandates that pharmaceutical companies collect, process, and forward ADR reports to relevant licensing authorities. The updated emphasis reinforces that pharmacovigilance is not optional but a core compliance requirement.
While large pharmaceutical companies typically have established pharmacovigilance systems and dedicated teams, smaller and mid-sized manufacturers may face challenges in meeting the enhanced expectations. Resource constraints, limited technical expertise, and gaps in awareness could slow down implementation for these players.
However, industry experts believe that the directive will push companies across the spectrum to invest in stronger systems, digital tools, and trained personnel to ensure compliance. Over time, this could lead to a more standardized and transparent safety monitoring ecosystem in India.
The CDSCO’s directive aligns India more closely with global regulatory practices, particularly in highly regulated markets such as the United States and Europe, where pharmacovigilance systems are rigorously enforced. For Indian pharmaceutical companies looking to expand their presence in these markets, compliance with such standards is becoming increasingly critical.
Enhanced pharmacovigilance capabilities not only reduce regulatory risks but also strengthen credibility among international partners and regulators. As global pharmaceutical supply chains evolve, buyers are placing greater emphasis on traceability, safety data, and compliance history when selecting manufacturing partners.
Also Read: Impact of Digital Transformation on Pharmacovigilance Efficiency and Accuracy
Beyond compliance, the directive underscores a broader strategic shift within the pharmaceutical industry. Drug safety is no longer confined to regulatory obligations but is emerging as a key differentiator in global markets.
Companies that proactively strengthen their pharmacovigilance frameworks can gain a competitive edge by demonstrating higher standards of quality and patient safety. Conversely, those that lag in implementation may face increased scrutiny, regulatory delays, or restricted market access.
The CDSCO’s mandate marks a significant step in reinforcing India’s drug safety architecture. By making pharmacovigilance systems mandatory and enforceable, the regulator is pushing the industry toward greater accountability, transparency, and global alignment, an essential move as India continues to anchor the global generic drug supply chain.
.jpg)
